Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04166149 · ClinicalTrials.gov registry record
Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA
A clinical trial, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- 140
- Enrollment target
NCT04166149: Completed study, sponsored by University of Maryland, Baltimore.
NCT04166149 is a clinical trial that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 140 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04166149 has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- 140 participants
- Enrollment target
Study Summary
Donor-derived cell-free DNA (dd-cfDNA) has shown promise as an early marker for cellular injury caused by rejection. dd-cfDNA changes may also indicate other injuries that lead to progressive decline in transplant organ function associated with, in the case of kidney transplantation, the presence of interstitial fibrosis (IF) and tubular atrophy (TA) seen in biopsy specimens. Here, we will study the utility of dd-cfDNA to predict rejection in pancreas and pancreas-kidney recipients.
Primary Outcome
To correlate circulating dd-cfDNA to clinical and sub-clinical acute rejection in PTA, PAK, and SPK allograft recipients. 1. Clinical T cell as well as antibody mediated acute rejection. 2. Sub-clinical T cell as well as antibody mediated acute rejection. 3. Composite of clinical and sub-clinical T cell as well as antibody mediated acute rejection.
Interventions
- DIAGNOSTIC_TEST dd-cfDNA Blood Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2024-09-06 |
What the finished NCT04166149 record still lists
NCT04166149 is an observational study that tracks outcomes without assigning an intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which dd-cfDNA Blood Test is the first listed.
NCT04166149 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04166149 about?
NCT04166149 is a clinical study titled "Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA". Donor-derived cell-free DNA (dd-cfDNA) has shown promise as an early marker for cellular injury caused by rejection. dd-cfDNA changes may also indicate other injuries that lead to progressive decline in transplant organ function associated with, in the case of kidney transplantation, the presence of...
What is the current status of trial NCT04166149?
This trial is currently completed. The enrollment target is 140 participants. The study started on 2019-09-01. Estimated completion is 2024-09-06.
What interventions are being tested in trial NCT04166149?
The interventions under investigation include: dd-cfDNA Blood Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04166149?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI